GlassScriptPhysician profile
Debra K Hall
NPI 1811034861
$12,405.82
in general payments reported to CMS, 2019-2025
57 companies · $1,806 in 2025
The $1,806 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,574 · 2020: $1,382 · 2021: $1,844 · 2022: $1,707 · 2023: $1,608 · 2024: $2,486 · 2025: $1,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,880 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,880.04 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,932.09 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,041.02 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,031.23 | 2019-2025 | Mounjaro, Zepbound, Amyvid |
| Biogen, INC. | $992.72 | 2021-2025 | Vumerity, Tysabri, Leqembi |
| Pfizer INC. | $967.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $838.03 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $599.32 | 2019-2025 | Otezla, Repatha, Repatha |
| Ucb, INC. | $523.37 | 2023-2025 | Rystiggo, Briviact, Nayzilam |
| Novo Nordisk INC | $473.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $356.33 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $346.72 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $326.98 | 2019-2024 | Hyqvia |
| Biohaven Pharmaceutical Holding Company LTD. | $281.33 | 2022 | |
| Astellas Pharma US INC | $222.83 | 2019-2023 | Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.58 | 2019-2025 | Jardiance |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.